Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6530320 | 1.00 | NFKB1 (0.43) | NFKB1NFKB2RELA | |
| SCHEMBL23782042 | 1.00 | NFKB1 (0.43) | NFKB1NFKB2RELA | |
| SCHEMBL14838051 | 1.00 | NFKB1 (0.43) | NFKB1NFKB2RELA | |
| SCHEMBL19606034 | 0.93 | NFKB1 (0.41) | NFKB1NFKB2RELA | |
| SCHEMBL24584247 | 0.93 | NFKB1 (0.41) | NFKB1NFKB2RELA | |
| SCHEMBL24754820 | 0.93 | NFKB1 (0.41) | NFKB1NFKB2RELA | |
| SCHEMBL24963813 | 0.93 | NFKB1 (0.41) | NFKB1NFKB2RELA | |
| Hydrochloric Acid SCHEMBL30800270 | 0.92 | — | — | |
| SCHEMBL23824564 | 0.92 | CTSL (0.51) | — | |
| SCHEMBL23824275 | 0.92 | CTSL (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605301-B | Method for preparing Pa Luo Weide intermediate | 江苏恒沛药物科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-115073347-A | Preparation method of lactam ring pharmaceutical intermediate | 浙江江北药业有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-114605301-A | Method for preparing intermediate of palovir | 江苏恒沛药物科技有限公司 | 2022-06-10 | — | — | CN | claimed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240270721-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2024-08-15 | — | — | US | disclosed |
| CN-115557871-B | Synthesis method of antiviral compound PF-07321332 | 杭州科巢生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-115322130-B | Preparation of (S) -2- (BOC-amino) -3- [ (S) -2-oxo-3-pyrrolidinyl ] propanoic acid methyl ester | 南京正济医药研究有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-115322130-B | Preparation of (S) -2- (BOC-amino) -3- [ (S) -2-oxo-3-pyrrolidinyl ] propanoic acid methyl ester | 南京正济医药研究有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024089159-A1 | MAIN PROTEASE INHIBITORS | UBIQ HOLDING B.V. (NL) | 2024-05-02 | — | — | WO | disclosed |
| EP-2970224-B1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140336106-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-7462594-B2 | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-09 | — | — | US | disclosed |
| US-20080125375-A1 | PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-05-29 | — | — | US | disclosed |
| US-7304088-B2 | Peptide like compounds for treating coronavirus or hepatitis C virus; severe acute respiratory distress syndrome | TAIGEN BIOTECHNOLOGY (TW) | 2007-12-04 | — | — | US | disclosed |
| US-20050143320-A1 | Protease inhibitors | TAIGEN BIOTECHNOLOGY | 2005-06-30 | — | — | US | disclosed |
| US-20050143319-A1 | Protease inhibitors | TAIGEN BIOTECHNOLOGY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143319-A1 | Protease inhibitors | PREP, SERPINB1, SPINT2 | NFKB1 2165/4885NFKB2 3054/4885RELA 2489/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | NFKB1 2618/4885NFKB2 3505/4885RELA 4568/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | NFKB1 3592/4885NFKB2 4176/4885RELA 4299/4885 |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | NFKB1 768/4885NFKB2 1452/4885RELA 2140/4885 |
| US-20140336106-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | NFKB1 768/4885NFKB2 1452/4885RELA 2140/4885 |
| US-20240270721-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | NFKB1 3533/4885NFKB2 3915/4885RELA 4244/4885 |
| US-20050143320-A1 | Protease inhibitors | PREP, SPINT2, SERPINB1 | NFKB1 2382/4885NFKB2 2721/4885RELA 2459/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | NFKB1 3592/4885NFKB2 4176/4885RELA 4299/4885 |
| US-20080125375-A1 | PROTEASE INHIBITORS | PREP, SERPINB1, SPINT2 | NFKB1 2165/4885NFKB2 3054/4885RELA 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.